CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type І Diabetes
CRISPR Therapeutics and ViaCyte announced that Health Canada had approved the companies' Clinical Trial Application (CTA) for VCTX210, an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type І diabetes (T1D). Initiation of patient enrollment is expected by year-end.
Phase І clinical trials are designed to assess its safety, tolerability, and immune evasion in patients with T1D. This program is being advanced as part of strategic collaboration to discover, develop, and commercialize gene-editable stem cell therapies for diabetes. CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. It has established a portfolio of therapeutic programs across a broad range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company has established strategic collaborations with leading companies, including Bayer, Vertex Pharmaceuticals, and ViaCyte, Inc.
ارسال به دوستان